Micro RNA‐4651 Serves as a Potential Biomarker for Prognosis When Selecting Hepatocellular Carcinoma Patients for Postoperative Adjuvant Transarterial Chemoembolization Therapy

• DOI: 10.1002/hep4.1245
• Publication Date: 2018-09-24T13:17:18Z
• Authors: Tian‐Qi Zhang; Qun‐Qing Su; Xiao‐Ying Huang; Jin‐Guang Yao; Chao Wang; Qiang Xia; Xi‐Dai Long; Yun Ma
• Keywords: Liver Cancer

Our previous reports have shown that microRNA-4651 is a potential early diagnostic and prognostic marker for hepatocellular carcinoma. We aimed to investigate whether modified postoperative adjuvant transarterial chemoembolization (pa-TACE) improve the prognosis of A hospital-based retrospective study, including 302 patients with advanced-stage carcinoma who received tumor resection or plus pa-TACE as an initial therapy, was conducted assess effects on treatment. MicroRNA-4651 expression in tissues tested using TaqMan-PCR technique. The sensitivity cells doxorubicin (an anticancer drug used procedure) analyzed by half-maximal inhibitory concentration (IC50). Upregulated can therapeutic response (hazard ratios [95% confidence intervals] = 0.32 [0.22-0.46] death risk 0.39 [0.28-0.56] tumor-recurrence risk, respectively), but downregulated cannot. Functional analyses-displayed mimics decreased while its inhibitor increased IC50 (0.65 [0.61-0.69] versus 2.17 [1.98-2.37] µM). Cytochrome P450 2W1 possible target microRNA-4651. Additionally, dysregulation also affected clinical pathological features independent factor this cancer. Conclusion: These results indicate increasing may be beneficial improving prognosis.